Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Apr 2:rs.3.rs-4121735.
doi: 10.21203/rs.3.rs-4121735/v1.

Rare variants in genes coding for components of the terminal pathway of the complement system in preeclampsia

Affiliations

Rare variants in genes coding for components of the terminal pathway of the complement system in preeclampsia

A Lokki et al. Res Sq. .

Update in

Abstract

Preeclampsia is a common multifactorial disease of pregnancy. Dysregulation of the complement activation is among emerging candidates responsible for disease pathogenesis. In a targeted exomic sequencing study we identified 14 variants within nine genes coding for components of the membrane attack complex (MAC, C5b-9) that are associated with preeclampsia. We found two rare missense variants in the C5 gene that predispose to preeclampsia (rs200674959: I1296V, OR (CI95) = 24.13 (1.25-467.43), p-value = 0.01 and rs147430470: I330T, OR (CI95) = 22.75 (1.17-440.78), p-value = 0.01). In addition, one predisposing rare variant and one protective rare variant were discovered in C6 (rs41271067: D396G, OR (CI95) = 2.93 (1.18-7.10), p-value = 0.01 and rs114609505: T190I, 0.02 OR (CI95) = 0.47 (0.22-0.92), p-value = 0.02). The results suggest that variants in terminal complement pathway predispose to preeclampsia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AJ serves on the Scientific advisory boards of Alexion, AstraZeneca Rare Disease, and Novartis International AG, and serves as a consultant for Dianthus Therapeutics and Aurinia Pharmaceuticals. She has been a principal investigator for Apellis Pharmaceuticals and Novartis International AG. She also received royalty from UptoDate. HL received honoraria from Orion Corporation. JPA is part of the Scientific Advisory Board of Complement Corporation and Kypha, Inc., Scientific Advisory Board. Furthermore, he served as a consultant in Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc., Biothera and Clinical Pharmacy Services, CDMI. SM received honoraria from Alexion, AstraZeneca Rare Disease, Biogen, Merck, Pfizer, and UCB, and research funding from Alexion.

Figures

Figure 1
Figure 1
(A) The domain structure of C5b (top) and C6 (bottom) with PE associating variants indicated. The C5 variants are located in exon 31/41 (I330) coding the Immunoglobulin-like domain 3 (MG3) and in exon 9/41 (I1296) coding the conserved complement-activating CUB (complement C1r/C1s, Uegf, Bmp1) domain Both C6 variants in exons 6/16 (T190) and 12/16 (D396) are located in the membrane attack complex/perforin domain (MACPF). (B) The protein structure of C6 (orange) in complex with C5b (green) with the PE-associating amino acids’ positions indicated. The D396 is located directly in the interaction site between the two molecules. The structural model is based on construct 4A5W (37).

References

    1. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013;209(6):544.e1–544.e12. - PubMed
    1. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013;170(1):1–7. - PubMed
    1. Van Lerberghe W, Manuel A, Matthews Z, Cathy W. The World Health Report 2005 - make every mother and child count. World Health Organization; 2005.
    1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–7. - PubMed
    1. Salonen Ros H, Lichtenstein P, Lipworth L, Cnattingius S. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet. 2000;91(4):256–60. - PubMed

Publication types

LinkOut - more resources